P. Statkevich

发表

Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer.

J. Nemunaitis, M. Edelman, J. Stephenson, 2014, Lung cancer.

Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome

P. Statkevich, G. Krishna, M. Abutarif, 2010, Current medical research and opinion.

Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment

R. Preston, D. Cutler, T. Kosoglou, 2012, European Journal of Clinical Pharmacology.

Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease

Lei Ma, L. Jennings, W. Kraft, 2012, European Journal of Clinical Pharmacology.

Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.

L. Grochow, R. Donehower, S. Baker, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Evaluation of the exposure equivalence of oral versus intravenous temozolomide

M. Cantillon, D. Cutler, P. Statkevich, 2009, Cancer Chemotherapy and Pharmacology.

Temozolomide in Patients with Advanced Cancer: Phase I and Pharmacokinetic Study

R. Donehower, S. Baker, M. Rudek, 2004, Pharmacotherapy.

Randomized P hase I II S tudy o f T emozolomide V ersus Dacarbazine i n t he T reatment o f P atients W ith A dvanced Metastatic M alignant M elanoma

D. Schadendorf, M. Gore, N. Aaronson, 2000 .

Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.

G. Weiss, D. V. Von Hoff, S. Baker, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide

P. Beale, I. Judson, M. Brada, 1999, Cancer Chemotherapy and Pharmacology.

Phase I a nd P harmacokinetic S tudy o f T emozolomide on a D aily-for-5-Days S chedule i n P atients With A dvanced S olid M alignancies

G. Weiss, S. Baker, D. V. Hoff, 1999 .

Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.

L. Grochow, R. Donehower, S. Baker, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) with relapsed/refractory CLL.

J. Byrd, N. Heerema, K. Blum, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin

D. Cutler, I. Meyer, T. Kosoglou, 2004, Current medical research and opinion.

Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors.

M. Piccart, J. Verweij, A. Sparreboom, 2001, Journal of Clinical Oncology.

Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors

Edward S. Kim, W. R. Bishop, P. Thall, 2004, Clinical Cancer Research.

Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors

C. Castañeda, H. Hurwitz, S. Kaufmann, 2011, Cancer Chemotherapy and Pharmacology.

Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Weekly Paclitaxel in Patients with Solid Tumors

R. Bukowski, N. Ready, A. Lipton, 2007, Clinical Cancer Research.

Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors.

M. Piccart, J. Verweij, A. Sparreboom, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single‐agent therapy with imatinib

G. Daley, H. Kantarjian, J. Cortes, 2007, Cancer.

High-performance liquid chromatographic analysis and stability of anti-tumor agent temozolomide in human plasma.

A. Nomeir, P. Statkevich, C. Lin, 2001, Journal of pharmaceutical and biomedical analysis.

Disposition and pharmacokinetics of temozolomide in rat

P. Statkevich, V. Batra, J. Patrick, 2004, Xenobiotica; the fate of foreign compounds in biological systems.

High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma.

A. Nomeir, P. Statkevich, C. Lin, 1997, Journal of chromatography. B, Biomedical sciences and applications.

Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin

D. Cutler, T. Kosoglou, P. Statkevich, 2012, European Journal of Clinical Pharmacology.

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

J. Nemunaitis, P. Kirschmeier, Ying‐Ming Jou, 2013, Journal of Translational Medicine.

On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia

G. Martinelli, T. Holyoake, J. Lipton, 2008, Leukemia.

ORIGINAL ARTICLE On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia

T. Holyoake, D. DeAngelo, P. Kirschmeier, 2008 .

Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study.

I. Pollack, P. Kirschmeier, R. Packer, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers

D. Cutler, T. Kosoglou, J. Rotonda, 2017, Clinical pharmacology in drug development.

Effect of the thrombin receptor antagonist (PAR‐1) vorapaxar on QT/QTc interval in healthy volunteers: A randomized, placebo‐ and positive‐controlled, parallel group trial

D. Cutler, T. Kosoglou, P. Statkevich, 2014, Clinical pharmacology in drug development.

The Effect of Multiple Doses of Ketoconazole or Rifampin on the Single‐ and Multiple‐Dose Pharmacokinetics of Vorapaxar

D. Cutler, T. Kosoglou, P. Statkevich, 2013, Journal of clinical pharmacology.

The Influence of Multiple‐Dose Vorapaxar, an Oral PAR‐1 Receptor Antagonist, on the Single‐Dose Pharmacokinetics and Pharmacodynamics of Digoxin

D. Cutler, T. Kosoglou, P. Statkevich, 2013, Clinical pharmacology in drug development.

Lack of Clinically Relevant Interaction Between Desloratadine and Erythromycin

C. Banfield, M. Affrime, D. Padhi, 2002, Clinical pharmacokinetics.

Disposition of loratadine in healthy volunteers

R. Clement, K. Alton, S. Chowdhury, 2007, Xenobiotica; the fate of foreign compounds in biological systems.

Phase I Study of Lonafarnib (SCH66336) in Combination with Imatinib for Patients (Pts) with Chronic Myeloid Leukemia (CML) after Failure to Imatinib.

G. Daley, H. Kantarjian, J. Cortes, 2004 .

Treating cancer with PEG Intron

R. Bukowski, D. Cutler, P. Statkevich, 2002, Cancer.

Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers*

M. Seiberling, T. Kosoglou, P. Statkevich, 2004, Current medical research and opinion.

Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types.

V. Ivaturi, V. Goodman, J. Gobburu, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies

Jason Zhang, P. Statkevich, Yan Feng, 2019, CPT: pharmacometrics & systems pharmacology.

Model-based assessment of benefit-risk profile of nivolumab (NIVO) flat dosing schedules (Q2W and Q4W) across multiple tumor types.

V. Ivaturi, J. Gobburu, X. Zhao, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Disposition of desloratadine in healthy volunteers

K. Alton, S. Chowdhury, P. Statkevich, 2005, Xenobiotica; the fate of foreign compounds in biological systems.

Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design.

P. Ascierto, J. Larkin, M. Sznol, 2020, Future oncology.

The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe

D. Cutler, T. Kosoglou, P. Statkevich, 2005, Current medical research and opinion.

Ezetimibe does not affect the pharmacokinetics of oral contraceptives

E. Sellers, D. Cutler, T. Kosoglou, 2001 .

Pharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibitor ezetimibe

M. Guillaume, D. Cutler, M. Affrime, 2001 .

Bioequivalence of an ezetimibe/simvastatin combination tablet and coadministration of ezetimibe and simvastatin as separate tablets in healthy subjects.

J. Paolini, A. Bergman, B. Yi, 2006, International journal of clinical pharmacology and therapeutics.

Disposition of desloratadine in healthy volunteers

R. Clement, K. Alton, S. Chowdhury, 2005, Xenobiotica; the fate of foreign compounds in biological systems.

Posaconazole Pharmacokinetics, Safety, and Tolerability in Subjects With Varying Degrees of Chronic Renal Disease

S. Swan, W. Smith, T. Marbury, 2005, Journal of clinical pharmacology.

Assessment of The Pharmacokinetic (PK), Pharmacodynamic (PD) Interaction Potential Between Posaconazole and Glipizide in Healthy Volunteers

R. Courtney, P. Statkevich, M. Martinho, 2003 .

Renal Disposition and Drug Interaction Screening of (–)-2′-deoxy-3′-thiacytidine (3TC) in the Isolated Perfused Rat Kidney

P. Statkevich, P. Hsyu, K. Sweeney, 1995, Pharmaceutical Research.

Ezetimibe

J. Paolini, A. Bergman, K. Alton, 2005, Clinical pharmacokinetics.

Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects.

R. Iannucci, M. Cayen, M. Affrime, 2002, Drug metabolism and disposition: the biological fate of chemicals.

Characterization of methotrexate elimination and interaction with indomethacin and flurbiprofen in the isolated perfused rat kidney.

P. Statkevich, K. Sweeney, D. Fournier, 1993, The Journal of pharmacology and experimental therapeutics.

Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies

P. Beale, M. Brada, D. Cutler, 1999, British Journal of Cancer.

A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.

D. V. Von Hoff, C. Britten, S. Baker, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies

Jennifer L Moseley, L. Chirieac, G. Shapiro, 2017, British Journal of Cancer.

Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies

G. Shapiro, M. Mita, Da Zhang, 2012, Cancer Chemotherapy and Pharmacology.

Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer.

C. Shapiro, M. Mita, A. Mita, 2014, Clinical breast cancer.

A phase I study of the CDK inhibitor dinaciclib (SCH 727965) administered every 3 weeks in patients (pts) with advanced malignancies: Final results.

L. Chirieac, G. Shapiro, S. Rodig, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of SCH 727965, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies.

J. Nemunaitis, P. Kirschmeier, D. Khaira, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group.

M. Stevens, C. R. Pinkerton, I. Lewis, 1998, British Journal of Cancer.

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.

D. Schadendorf, N. Aaronson, M. Muller, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson–Gilford progeria syndrome

A. Giobbie-Hurder, D. Neuberg, A. Schwartzman, 2012, Proceedings of the National Academy of Sciences.

A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan.

N. Kemeny, L. Saltz, D. Kelsen, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid Tumors

S. Agrawal, I. Waxman, P. Statkevich, 2017, Journal of clinical pharmacology.

A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe.

T. Kosoglou, P. Statkevich, V. Batra, 2001, Clinical therapeutics.

Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane‐refractory/resistant nonsmall cell lung carcinoma

Edward S. Kim, F. Khuri, K. Pisters, 2005, Cancer.

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

A. Tolcher, C. Geyer, L. Denis, 2003, British Journal of Cancer.

Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid Tumors

Jason Zhang, H. Vezina, P. Statkevich, 2019, CPT: pharmacometrics & systems pharmacology.

The Plasma Concentration and LDL‐C Relationship in Patients Receiving Ezetimibe

D. Wexler, T. Kosoglou, P. Statkevich, 2001, Journal of clinical pharmacology.

Update on the Phase I Study of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity and Feasibility of Long-Term Administration

Jeffrey A Jones, M. Grever, J. Byrd, 2010 .

A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the novel cyclin-dependent kinase inhibitor SCH 727965 administered every 3 weeks in subjects with advanced malignancies

Jennifer L Moseley, G. Shapiro, C. Takimoto, 2008 .

Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours.

M. Piccart, J. Wanders, J. Verweij, 2002, European journal of cancer.

Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin

D. Cutler, M. Affrime, I. Meyer, 2002 .

Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin.

D. Cutler, M. Affrime, I. Meyer, 2000, British journal of clinical pharmacology.

Vorapaxar, an oral PAR‐1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone

T. Kosoglou, P. Statkevich, M. Hanson, 2015, Clinical pharmacology in drug development.

Exposure–Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma

P. Statkevich, G. Bajaj, Yan Feng, 2017, Journal of clinical pharmacology.

A Phase I Multicenter Study of Continuous Oral Administration of Lonafarnib (SCH 66336) and Intravenous Gemcitabine in Patients With Advanced Cancer

H. Hurwitz, S. Kaufmann, A. Adjei, 2011, Cancer investigation.

Assessment of pharmacokinetic interactions between ezetimibe and cyclosporine

J. Paolini, A. Bergman, T. Kosoglou, 2005 .

Pharmacodynamic interaction between ezetimibe and rosuvastatin

R. Suresh, D. Cutler, T. Kosoglou, 2004, Current medical research and opinion.

1119 Electrocardiographic effects of multiple high doses of desloratadine

C. Banfield, M. Affrime, D. Padhi, 2000 .

The Cyclin Dependent Kinase Inhibitor SCH 727965 Demonstrates Promising Pre-Clinical and Early Clinical Activity in Chronic Lymphocytic Leukemia.

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2009 .

Nivolumab Clearance Is Stationary in Patients With Resected Melanoma on Adjuvant Therapy: Implications of Disease Status on Time‐Varying Clearance

A. Bello, P. Statkevich, G. Bajaj, 2019, Clinical pharmacology and therapeutics.

Pharmacodynamic and pharmaco-kinetic interaction between fenofibrate and ezetimibe*

J. Fruchart, M. Guillaume, D. Cutler, 2004, Current medical research and opinion.

Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment

R. Preston, T. Kosoglou, P. Statkevich, 2012, European Journal of Clinical Pharmacology.

Effects of Ezetimibe on Cyclosporine Pharmacokinetics in Healthy Subjects

J. Paolini, W. Kraft, H. Greenberg, 2006, Journal of clinical pharmacology.

Interaction of Single‐Dose Ezetimibe and Steady‐State Cyclosporine in Renal Transplant Patients

J. Paolini, A. Bergman, R. Robson, 2006, Journal of clinical pharmacology.

Abstract CT101: A model-based exposure-response (E-R) assessment of a nivolumab (NIVO) 4-weekly (Q4W) dosing schedule across multiple tumor types

V. Ivaturi, V. Goodman, J. Gobburu, 2017 .

Abstract 2242: A randomized phase 2 study of the cyclin-dependent kinase (CDK) inhibitor Dinaciclib (SCH 727965) in patients with non-small cell lung cancer (NSCLC)

J. Nemunaitis, M. Edelman, J. Stephenson, 2011 .

Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjects.

Xia Chen, Ji Jiang, P. Hu, 2014, International journal of clinical pharmacology and therapeutics.

Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin

D. Cutler, T. Kosoglou, P. Statkevich, 2012, European Journal of Clinical Pharmacology.

Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease

L. Jennings, W. Kraft, T. Kosoglou, 2012, European Journal of Clinical Pharmacology.

Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects

T. Kosoglou, P. Statkevich, Yali Zhu, 2011, European Journal of Clinical Pharmacology.

Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil.

M. Affrime, T. Kosoglou, P. Statkevich, 2004, International journal of clinical pharmacology and therapeutics.

Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results

P. Ascierto, M. Sznol, H. Gogas, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Absence of a Clinically Significant Effect of Food on the Single Dose Pharmacokinetics of Vorapaxar, a PAR‐1 Antagonist, in Healthy Adult Subjects

T. Kosoglou, P. Statkevich, M. Martinho, 2013, Clinical pharmacology in drug development.

Effect of the thrombin receptor antagonist (PAR‐1) vorapaxar on QT/QTc interval in healthy volunteers: A randomized, placebo‐ and positive‐controlled, parallel group trial

T. Kosoglou, P. Statkevich, M. Hanson, 2014, Clinical pharmacology in drug development.